Sponsor or institution

Clinical trials and research at Shandong Cancer Hospital and Institute

• 38Clinical trials
• 1Country

Newest trials

All recruiting trials (38)

• 177Lu-FAP-VG11 Injection for FAP-Positive Advanced Solid Tumours

  A first-in-class, early-dose study tests whether 177Lu-FAP-VG11 can be safely given to adults with FAP-positive advanced solid tumours who have few other options.

  Recruiting Early Phase 1 Shandong Cancer Hospital and Institute · Jinan, Shandong · NCT07808177

• Short-Course Radiotherapy Followed by CAPOX With or Without Iparomlimab and Tuvonralimab in Localized Rectal Cancer

  In people with locally advanced, treatment-naive rectal cancer, this study tests whether adding two immunotherapy drugs to a standard chemotherapy after short-course radiotherapy can improve tumor response.

  Recruiting Phase 3 Shandong Cancer Hospital and Institute · Jinan, Shandong · NCT07686640

• SBRT followed by a multi-drug immunotherapy and chemo regimen for locally advanced pancreatic cancer

  This trial tests whether giving SBRT followed by a combination of ipilimumab, sintilimab, nab-paclitaxel, and gemcitabine helps people with locally advanced pancreatic cancer.

  Recruiting Phase 2 Shandong Cancer Hospital and Institute · Jinan, Shandong · NCT07683221

• SBRT plus maintenance therapy vs maintenance therapy alone in advanced pancreatic cancer

  This trial tests whether adding targeted SBRT to ongoing maintenance therapy helps people with unresectable pancreatic cancer live longer than maintenance therapy alone.

  Recruiting Phase 2 Shandong Cancer Hospital and Institute · Jinan, Shandong · NCT07600268

• Concordance between a Large Language Model and a Multidisciplinary Team for Rectal Cancer

  A large language model will generate treatment recommendations for rectal cancer patients, and researchers will compare those to the real multidisciplinary team recommendations to see how closely they match.

  Recruiting Shandong Cancer Hospital and Institute · Jinan, Shandong · NCT07595107

• Nanocrystalline megestrol acetate for appetite and weight loss in advanced pancreatic cancer

  This trial tests whether adding a fast-absorbing form of megestrol acetate to standard first-line therapy helps people with advanced pancreatic cancer who have cachexia gain weight and improve appetite.

  Recruiting Shandong Cancer Hospital and Institute · Jinan · NCT07408505

• How very high HER2 levels affect outcomes after dual HER2 therapy in early breast cancer

  This project will see if people with very high HER2 levels (HER2/CEP17 ratio >7) do better or worse after getting trastuzumab plus pertuzumab for early-stage HER2-positive breast cancer.

  Recruiting Shandong Cancer Hospital and Institute · Jinan, Shandong · NCT07376174

• Proton versus photon radiation for advanced nasopharyngeal cancer

  This trial will test whether proton radiation (IMPT) or standard photon IMRT causes fewer severe side effects and improves 3-year progression-free survival for adults with newly diagnosed, high-risk locally advanced nasopharyngeal cancer who receive induction chemotherapy followed by concurrent chemoradiotherapy with i

  Recruiting Phase 3 Shandong Cancer Hospital and Institute · Jinan, Shandong · NCT07340515

• 225Ac-TR2205 treatment for advanced triple-negative breast cancer

  This trial will try 225Ac-TR2205, a targeted radioactive medicine, in adults with metastatic triple-negative breast cancer who have had at least two prior systemic treatments to see if it is safe, tolerable, and to gather early effectiveness and radiation dosimetry data.

  Recruiting Early Phase 1 Shandong Cancer Hospital and Institute · Jinan, Shandong · NCT07340424

• Radiotherapy with nimotuzumab versus radiotherapy alone for platinum-ineligible advanced head and neck squamous cell carcinoma

  This trial tests whether adding nimotuzumab to radiotherapy helps people with advanced head and neck squamous cell carcinoma who cannot receive platinum chemotherapy.

  Recruiting Phase 3 Shandong Cancer Hospital and Institute · Shandong, Province · NCT07333274

• NALIRIFOX with SBRT for locally advanced pancreatic cancer

  This study tests whether combining NALIRIFOX chemotherapy with SBRT is safe and effective for people with locally advanced unresectable pancreatic cancer.

  Recruiting Phase 2 Shandong Cancer Hospital and Institute · Jinan, Shandong · NCT07173387

• 225Ac-labeled FAPI-XT (XT117) injection for FAP-positive advanced solid tumors

  This treatment tests a targeted radioactive drug called [225Ac]Ac-FAPI-XT in adults with FAP-positive advanced solid tumors to see if it is safe and can slow or shrink tumors.

  Recruiting Phase 1 Shandong Cancer Hospital and Institute · Jinan, Shandong · NCT07135128

• Testing [225Ac]Ac-PSMA-XT, a PSMA-targeted alpha therapy, in men with metastatic castration‑resistant prostate cancer.

  This will try a PSMA-targeted radioactive drug called [225Ac]Ac-PSMA-XT to see if it is safe and helps men with metastatic castration‑resistant prostate cancer.

  Recruiting Phase 1 Shandong Cancer Hospital and Institute · Jinan, Shandong · NCT07135102

• Early screening for esophageal, stomach, and colorectal cancers

  This project will collect blood plasma from adults 40–75 who are having gastrointestinal cancer screening to test a multi-cancer early detection blood test for esophageal, gastric, and colorectal cancers.

  Recruiting Shandong Cancer Hospital and Institute · Jinan, Shandong · NCT07106424

• HAIC plus iparomlimab or tuvonralimab with bevacizumab, followed by SBRT for advanced liver cancer with portal vein involvement or limited metastases

  This trial will test whether giving hepatic artery infusion chemotherapy with an immune checkpoint antibody (iparomlimab or tuvonralimab) plus bevacizumab, followed by focused stereotactic radiation, helps people with advanced hepatocellular carcinoma that involves the portal vein or has a small number of metastases.

  Recruiting Phase 2 Shandong Cancer Hospital and Institute · Jinan, Shandong · NCT07062055

• Neoadjuvant tislelizumab with SBRT and gemcitabine/platinum chemotherapy for borderline or unresectable hilar bile duct cancer

  This trial will see if precise radiotherapy (SBRT) followed by the PD‑1 drug tislelizumab plus gemcitabine and platinum chemotherapy can shrink tumors enough to allow surgery and improve survival in people with borderline resectable or unresectable hilar cholangiocarcinoma.

  Recruiting Phase 2 Shandong Cancer Hospital and Institute · Jinan, Shandong · NCT07030140

• Iparomlimab and tuvonralimab added to total neoadjuvant therapy for pMMR/MSS locally advanced rectal cancer

  This study tests if adding the immunotherapies iparomlimab and tuvonralimab to total neoadjuvant chemoradiotherapy improves tumor response in people with pMMR/MSS locally advanced rectal cancer.

  Recruiting Phase 2 Shandong Cancer Hospital and Institute · Jinan, Shandong · NCT07026422

• Conversion therapy with surgery and targeted para‑aortic radiotherapy for gastric cancer with retroperitoneal (station 16) lymph node spread

  This trial tests whether chemotherapy (SOX with or without a PD‑1 inhibitor), followed by D2 gastrectomy and para‑aortic radiotherapy, helps people with gastric adenocarcinoma who have only para‑aortic lymph node metastases live longer without their cancer progressing compared with standard chemotherapy alone.

  Recruiting Phase 2 Shandong Cancer Hospital and Institute · Jinan, Shandong · NCT07007182

• Proton versus photon radiation for nasopharyngeal cancer

  This trial will test whether proton radiation works at least as well as standard photon radiation for adults newly diagnosed with nasopharyngeal cancer that has not spread.

  Recruiting Phase 3 Shandong Cancer Hospital and Institute · Jinan · NCT07000643

• Targeted radiotherapy (SFRT or SCART) for bone metastases with soft-tissue tumors

  This study will test whether two advanced radiation methods (SFRT or SCART) shrink the soft-tissue part of bone metastases better than conventional radiotherapy in adults with advanced cancer.

  Recruiting Shandong Cancer Hospital and Institute · Jinan, Shandong · NCT06987370

• Comparing two types of radiation therapy for soft tissue sarcoma

  This study is testing whether a new type of radiation therapy can work better than the standard treatment for people with soft tissue sarcoma that has a tumor size of at least 5 cm.

  Recruiting Shandong Cancer Hospital and Institute · Jinan, Shandong · NCT06980259

• Combining iparomlimab and tuvonralimab with chemotherapy and radiation for cervical cancer

  This study is testing if combining two new drugs with chemotherapy and radiation can help people with locally recurrent cervical cancer live longer and feel better.

  Recruiting Phase 2 Shandong Cancer Hospital and Institute · Jinan, Shandong Recruiting · NCT06942416

• Combining sintilimab, lenvatinib, and HAIC for treating borderline resectable liver cancer before surgery

  This study is testing if a combination of three treatments can help people with borderline resectable liver cancer do better in surgery compared to having surgery right away.

  Recruiting Phase 2 Shandong Cancer Hospital and Institute · Jinan, Shandong · NCT06904014

• Neoadjuvant treatment for rectal cancer using TAS-102 or capecitabine

  This study is testing if a new oral cancer medication called TAS-102 works better than the standard treatment, capecitabine, for people with locally advanced rectal cancer before surgery.

  Recruiting Phase 3 Shandong Cancer Hospital and Institute · Jinan, Shandong · NCT06850090

• Using Taurine to Prevent and Treat Skin Damage from Radiation in Breast Cancer Patients

  This study is testing whether applying taurine on the skin can help breast cancer patients prevent and heal skin damage caused by radiation treatment.

  Recruiting Phase 1/2 Shandong Cancer Hospital and Institute · Jinan, Shandong · NCT06847555

• Combining a new drug with radiation and chemotherapy for pancreatic cancer treatment

  This study is testing a new drug combined with radiation and chemotherapy to see if it helps people with locally advanced pancreatic cancer live longer without their disease getting worse.

  Recruiting Phase 1/2 Shandong Cancer Hospital and Institute · Jinan, Shandong · NCT06844422

• Comparing radiotherapy with early switch to second-line therapy for oligoprogressive HCC

  This study is testing whether adding radiotherapy to ongoing treatment helps people with hepatocellular carcinoma who have limited cancer growth, compared to switching to a different treatment sooner.

  Recruiting Phase 3 Shandong Cancer Hospital and Institute · Jinan, Shandong · NCT06841172

• Combining pazopanib with chemotherapy for treating recurrent rhabdomyosarcoma in children and adolescents

  This study is testing if combining a drug called pazopanib with chemotherapy can help children and teenagers with recurring rhabdomyosarcoma feel better and manage their symptoms.

  Recruiting Phase 2 Shandong Cancer Hospital and Institute · Jinan, Shandong · NCT06816771

• Combining Posaconazole with Pembrolizumab and Chemotherapy for Triple-Negative Breast Cancer

  This study is testing whether adding a medication called posaconazole to standard chemotherapy and pembrolizumab can help women with high-risk triple-negative breast cancer respond better to treatment before surgery.

  Recruiting Phase 2 Shandong Cancer Hospital and Institute · Jinan, Shandong · NCT06802757

• Delayed systemic therapy after local treatment for lung metastases in colorectal cancer patients

  This study is testing if waiting to start whole-body treatment after local treatment for lung cancer spots can be a good option for colorectal cancer patients who have been cancer-free for at least six months.

  Recruiting Phase 2 Shandong Cancer Hospital and Institute · Jinan, Shandong · NCT06778382

• Using cadonilimab with chemotherapy and radiation for advanced endometrial cancer

  This study is testing if adding cadonilimab to chemotherapy and radiation can help people with advanced endometrial cancer live longer and feel better.

  Recruiting Phase 2 Shandong Cancer Hospital and Institute · Jinan, Shandong · NCT06532539

• Combining Fruquintinib, Regorafenib, and Sintilimab with Radiotherapy for Advanced Colorectal Cancer

  This study is testing a new combination of three cancer drugs with or without radiation to see if it helps people with advanced colorectal cancer who have already tried other treatments.

  Recruiting Phase 2 Shandong Cancer Hospital and Institute · Jinan, Shandong · NCT06356584

• Treatment for resectable intrahepatic cholangiocarcinoma using a combination of drugs and chemotherapy

  This study is testing a new combination of drugs and chemotherapy to see if it can help people with resectable intrahepatic cholangiocarcinoma live longer and prevent the cancer from coming back after surgery.

  Recruiting Phase 2 Shandong Cancer Hospital and Institute · Jinan, Shandong · NCT06296563

• Combining camrelizumab with chemotherapy for lung cancer treatment

  This study is testing if combining a new drug called camrelizumab with chemotherapy can help people with certain types of lung cancer before surgery.

  Recruiting Phase 2 Shandong Cancer Hospital and Institute · Jinan, Shandong · NCT06241807

• Sintilimab combined with chemotherapy and radiotherapy for inoperable pancreatic cancer

  This study is testing if combining the immunotherapy drug Sintilimab with chemotherapy and radiotherapy can help people with inoperable pancreatic cancer live longer and feel better.

  Recruiting Phase 2 Shandong Cancer Hospital and Institute · Jinan, Shandong · NCT06050317

• Combining orelabrutinib with R-CHOP for treating newly diagnosed double expression DLBCL

  This study is testing if adding orelabrutinib to the standard R-CHOP treatment can help people newly diagnosed with a specific aggressive type of lymphoma feel better.

  Recruiting at 2 sites Phase 2 Shandong Cancer Hospital and Institute · Nanchang, Jiangxi and 1 other locations · NCT05933967

• Neoadjuvant treatment for ALK-positive or ROS1-positive lung cancer

  This study is testing a new pill called WX-0593 to see if it can shrink tumors in patients with a specific type of lung cancer before they have surgery.

  Recruiting Phase 2 Shandong Cancer Hospital and Institute · Jinan, Shandong · NCT05765877

• Comparing brain radiation to MRI monitoring in lung cancer patients after treatment

  This study is testing whether giving brain radiation can help prevent lung cancer from spreading to the brain better than just keeping an eye on it with MRI scans in patients who are in remission.

  Recruiting at 2 sites Phase 3 Shandong Cancer Hospital and Institute · Jinan, Shandong and 1 other locations · NCT04829708

Quick answers

How many clinical trials run by Shandong Cancer Hospital and Institute are recruiting right now?

38, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

All of them have sites in China. Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 19, Phase 3: 7, Phase 1/2: 2, Phase 1: 2. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →